18-fluorodeoxyglucose PET in people with active myelopathy Nov. 01, 2013 Overview Show transcript Overview Eoin P. Flanagan, M.B., B.Ch., an assistant professor of neurology and an Autoimmune Neurology fellow at Mayo Clinic in Rochester, Minnesota, discusses his article appearing in the November 2013 issue of Mayo Clinic Proceedings, which suggests that PET scans may give a clue to the underlying etiology in patients with spinal cord disease. Share Doximity Facebook LinkedIn Twitter Print details Receive Mayo Clinic news in your inbox. Sign up Related ContentArticleCombining PET scans and 7-tesla MRI to pinpoint subtle epileptogenic lesionsArticleMayo Clinic pancreatic cancer research is changing the paradigm for neoadjuvant therapy VID-20432774 Medical Professionals 18-Fluorodeoxyglucose PET in Patients with Active Myelopathy